Environmental factors and their impact on the intestinal microbiota: A role for human disease?

Digestive Diseases

Volumn 30, Issue SUPPL. 3, 2012, Pages 20-27

  Biedermann, Luc ^a   Rogler, Gerhard ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Inflammatory bowel disease; Microbiota; Smoking cessation; Ulcerative colitis

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; CYCLOSPORIN A; METRONIDAZOLE;

ARTICLE; BACTERIAL INFECTION; COLITIS; CROHN DISEASE; ENTERITIS; ENVIRONMENTAL FACTOR; GRAFT VERSUS HOST REACTION; HIGH THROUGHPUT SEQUENCING; HUMAN; INTESTINE FLORA; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; VIRUS INFECTION;

EID: 84872075315     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342590     Document Type: Article

References (81)

1. Savage DC: Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977;31:107-133.
2. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI: The human microbiome project. Nature 2007;449:804-810. (Pubitemid 47598620)
3. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI: Host-bacterial mutualism in the human intestine. Science 2005;307:1915-1920. (Pubitemid 40404694)
4. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI: Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005;102:11070-11075. (Pubitemid 41105994)
5. Lee YK, Mazmanian SK: Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010;330:1768-1773.
6. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL: An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118. (Pubitemid 40977944)
7. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE:: Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-1359. (Pubitemid 43839542)
8. Sonnenburg JL, Xu J, Leip DD, Chen C, Westove, BP, Weatherford J, Buhler JD, Gordon JI: Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 2005;307:1955-1959. (Pubitemid 40404703)
9. Guarner F, Malagelada J: Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol 2003;17:793-804.
10. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB:: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-5231. (Pubitemid 29044613)
11. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-774.
12. Codling C, O'Mahony L, Shanahan F, Quigley EMM, Marchesi JR: A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010;55:392-397.
13. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A:: The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterolog y 2007;133:24-33. (Pubitemid 47031125)
14. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-15723. (Pubitemid 39473554)
15. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT: Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:228-231.
16. Toivanen P: Normal intestinal microbiota in the aetiopathogenesis of rheumatoid arthritis. Ann R heum Dis 2003;62:807-811. (Pubitemid 37026488)
17. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, Wekerle H, Krishnamoorthy G: Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011;479:538-541.
18. Williams BL, Hornig M, Parekh T, Lipkin WI: Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. mBio 2012, DOI: 10.1128/mBio.00261-11.
19. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A: Colonic microbiome is altered in alcoholism. Am Journal Physiol - Gastrointest Liver Physiol 2012;302:966-978.
20. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA: Diversity of the human intestinal microbial flora. Science 2005;308:1635-1638. (Pubitemid 40807514)
21. Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS, Schlegel ML, Tucker TA, Schrenzel MD, Knight R, et al: Evolution of mammals and their gut microbes. Science 2008;320:1647-1651. (Pubitemid 351931256)
22. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, et al: A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.
23. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI: Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008;3:213-223. (Pubitemid 351494716)
24. Dinsdale EA, Edwards RA, Hall D, Angly F, Breitbart M, Brulc JM, Furlan M, Desnues C, Haynes M, Li L, et al: Functional metagenomic profiling of nine biomes. Nature 2008;452:629-632. (Pubitemid 351483360)
25. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031. (Pubitemid 46018515)
26. Ley RE, Turnbaugh PJ, Klein S, Gordon JI: Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-1023. (Pubitemid 46018512)
27. Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, Moreno LA, Veiga O, Redondo-Figuero C, Garagorri JM, et al: Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity 2009;17:1906-1915.
28. Woodard GA, Encarnacion B, Downey JR, Peraza J, Chong K, Hernandez-Boussard T, Morton JM: Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg 2009;13:1198-1204.
29. Elli M, Colombo O, Tagliabue A: A common core microbiota between obese individuals and their lean relatives? Evaluation of the predisposition to obesity on the basis of the fecal microflora profile. Med Hypotheses 2010;75:350-352.
30. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI: Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001;291:881-884. (Pubitemid 32120760)
31. Le Poul E, Loison C, Struyf S, Springael J, Lannoy V, Decobecq M, Brezillon S, Dupriez V, Vassart G, van Damme J, et al: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003;278:25481-25489. (Pubitemid 36835299)
32. Hotamisligil GS, Erbay E: Nutrient sensing and inf lammation in metabolic diseases. Nat Rev Immunol 2008;8:923-934.
33. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E: Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009;50:90-97.
34. Cani PD, Possemiers S, van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilit y. Gut 2009;58:1091-1103.
35. Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J: Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009;15:734-741.
36. Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR: Molecularphylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780-13785. (Pubitemid 350003397)
37. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW: The bacteriology of biopsies differs between newly diagnosed, untreated Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006;55:1141-1149. (Pubitemid 44215574)
38. Lucke K, Miehlke S, Jacobs E, Schuppler M: Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. J Med Microbiol 2006;55:617-624.
39. Manichanh C: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006;55:205-211. (Pubitemid 43117279)
40. Round JL, Mazmanian SK: The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-323.
41. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Doré J: Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003;52:237-242. (Pubitemid 36115065)
42. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, et al: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54. (Pubitemid 34049193)
43. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P: Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-481. e4.
44. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, Marshall JK, Talley NJ, Moayyedi P: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661-673.
45. Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, Mizokami Y, Sugiyama T, Yanaka A, Takeuchi Y, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010;105:1820-1829.
46. Mazmanian SK, Round JL, Kasper DL: A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625. (Pubitemid 351769307)
47. Hedl M, Li J, Cho JH, Abraham C: Chronic stimulation of NOD2 mediates tolerance to bacterial products. Proc Natl Acad Sci USA 2007;104:19440-19445.
48. Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009;361:2066-2078.
49. Sokol H, Lay C, Seksik P, Tannock GW: Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008;14:858-867. (Pubitemid 351898071)
50. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada J: Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008;103:643-648. (Pubitemid 351405965)
51. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S: Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004;53:685-693. (Pubitemid 38561447)
52. Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS: Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010;16:2034-2042.
53. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL: IBD what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012;9:219-230.
54. Mondot S, Kang S, Furet JP, Aguirre Carcer D de, McSweeney C, Morrison M, Marteau P, Doré J, Leclerc M: Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inf lamm Bowel Dis 2011;17:185-192.
55. Joossens M, Huys G, Cnockaert M, Preter V de, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S: Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-637.
56. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L: A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterolog y 2010;139:1844-1854. e1.
57. Fedorak RN, Dieleman LA: Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 2008;42(suppl 2):S97-S103.
58. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, et al: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesa lazine. Gut 2004;53:1617-1623. (Pubitemid 39434105)
59. Boudeau J, Glasser A, Julien S, Colombel J, Darfeuille-Michaud A: Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:45-56. (Pubitemid 36897980)
60. Ukena SN, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, et al: Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2007;2:e1308.
61. Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Adrio JL, Olivares M, Xaus J, Zarzuelo A, Galvez J: Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis 2006;21:737-746. (Pubitemid 44524027)
62. Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun WA: In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br J Nutr 2008;100:530-541.
63. Möndel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, Beisner J, Fellermann K, Stange EF, Wehkamp J: Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009;2:166-172.
64. van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D: Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microf lora. J Natl Cancer Inst 1974;52:401-404.
65. van Bekkum D, Vos O: Treatment of secondary disease in radiation chimaeras. Int J Radiat Biol 1961;3:173-181.
66. Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549. (Pubitemid 34293433)
67. Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, Elson CO: CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998;187:855-864. (Pubitemid 28141659)
68. Brandon JA, Jennings CD, Kaplan AM, Bryson JS: Murine syngeneic graft-versushost disease is responsive to broad-spectrum antibiotic therapy. J Immunol 2011;186:3726-3734.
69. Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H, Shimoda S, Iwasaki H, Shimono N, Ayabe T, et al: Graft-versushost disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012;120:223-231.
70. Heimesaat MM, Nogai A, Bereswill S, Plickert R, Fischer A, Loddenkemper C, Steinhoff U, Tchaptchet S, Thiel E, Freudenberg MA, et al: MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 2010;59:1079-1087.
71. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S: Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006;81:1462-1471. (Pubitemid 44687433)
72. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP: Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996;110:424-431. (Pubitemid 26043875)
73. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, et al: Ulcerative colitis: patient characteristics may predict 10-year disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102:1692-1701. (Pubitemid 47206689)
74. Kane SV, Flicker M, Katz-Nelson F: Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol 2005;39:32-35. (Pubitemid 40041340)
75. Breuer-Katschinski BD, Hollãnder N, Goebell H: Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996;8:225-228.
76. Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre J P, Cosnes J: I mpac t of ce ssat ion of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001;96:2113-2116. (Pubitemid 32660906)
77. Birrenbach T, Böcker U: In f lammator y bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis 2004;10:848-859. (Pubitemid 39549299)
78. Rudra T, Motley R, Rhodes J: Does smoking improve colitis? Scand J Gastroenterol Suppl 1989;170:61-63; discussion 66-68. (Pubitemid 20015826)
79. O'Hara P, Connett JE, Lee WW, Nides M, Murray R, Wise R: Early a nd late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol 1998;148:821-830. (Pubitemid 28484100)
80. Rodin J: Weight change following smoking cessation: the role of food intake and exercise. Addict Behav 1987;12:303-317.
81. Stamler J, Rains-Clearman D, Lenz-Litzow K, Tillotson JL, Grandits GA: Relation of smoking at baseline and during trial years 1-6 to food and nutrient intakes and weight in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr 1997;65:374S-402S. (Pubitemid 27020451)